Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Practical Experience With Lenvatinib/Everolimus in RCC 

mTOR/TKI Combination Therapy in Kidney Cancer

Role of mTOR Inhibition in Kidney Cancer

Frontline TKI Strategies in Kidney Cancer

Kidney Cancer: Continuing to Improve Survival 

Understanding the Biology of Kidney Cancer

The explosion of new checkpoint immunotherapy drugs has changed the paradigm of care for patients with urothelial carcinoma, the most common form of bladder cancer.

Experts Discuss Immunotherapy's Evolution in Bladder Cancer

Immunotherapy for Operable NSCLC 

Novel Immunotherapy Combinations for NSCLC 

Emerging Immunotherapies and Combinations for NSCLC 

Unmet Needs: Sequencing After Immunotherapy in NSCLC 

Questions Surrounding Therapeutic Sequencing for NSCLC 

Immunotherapy for Relapsed/Refractory NSCLC 

Early Experience; Immunotherapy + Chemotherapy for NSCLC

Upfront Immunotherapy + Chemotherapy for NSCLC

Upfront Immunotherapy for NSCLC

The Ever-Evolving Treatment Paradigm for NSCLC

Following treatment with single-agent nivolumab (Opdivo), patients with head and neck squamous cell carcinoma saw improved or stable quality of life scores.

Nivolumab Associated With Improved QoL in Head and Neck Cancer

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

Dr. Petrylak on Combinations with Pembrolizumab in Urothelial Carcinoma

The future of treatment for ovarian cancer may lie in immunotherapy combinations with PARP inhibitors or checkpoint inhibitors.

Therapy Combinations May Become the Treatment of Choice in Ovarian Cancer

Immuno-Oncology

Immuno-Oncology | Specialty